Four times a year, we read the sources you don’t have time to read. What moved, what it means, and what to do about it: filtered to your therapy area and geography.
Enterprise platforms write for markets. This report is written for you, at your company, for the decisions you're making this quarter.
Enterprise commercial intelligence platforms write for sectors and categories. If you want one to write for your specific commercial position, it'll cost you fifty thousand pounds and twelve months of a procurement process. This report costs less than a day's consultancy and arrives in the first week of the quarter.
The intelligence it contains isn't secret. It's in public sources: procurement portals, regulatory filings, Companies House accounts, clinical trial registers, NHS board papers. The problem isn't access. It's time.
Senior commercial leaders in medical devices aren't short of expertise. They're short of the 48 hours it takes to read an MHRA safety notice, a competitor's earnings call, an ICB commissioning consultation that signals a tender consolidation fourteen months out. By the time those signals reach you through normal channels, the window to act on them has usually closed.
Four times a year, we read those sources for you. One therapy area. One geography. Fourteen sections, each verified against a named source or declared absent. No estimates without disclosure. No padding.
And because it comes from outside your organisation, it hasn't been through the filter. Nobody on your team decided what you should and shouldn't see.
Four times a year, we read those sources for you. One therapy area. One geography. Fourteen sections, each verified against a named source or declared absent. No estimates without disclosure. No padding.
The May 2026 UK Home Oxygen report landed on a Commercial Director's desk on a Tuesday. By Thursday he had three actions he hadn't known to look for: a trust with a procurement window his competitors hadn't spotted, a competitor field force restructure, and a clinical development that changed how he positioned his next tender submission. He didn't search for any of it.
That's the product.
Every issue ends here. Three things. Not a summary of what you've read. Three specific actions, ranked by commercial urgency, that a market-aware leader in your therapy area should consider acting on before the next issue arrives. They're short, direct, and deliberately opinionated. If you read nothing else in the report, read this section and decide whether you agree.
You're not always going to read the full report. The Executive Summary is written for that reality. It pulls the three to five most commercially consequential developments from the quarter into a single page: what happened, why it matters, and what a market-aware commercial leader should be thinking about as a result. It's the version you read before a board meeting, a client pitch, or a conversation with a distributor who thinks they know more than you do.
Markets don't announce themselves. Trends arrive as noise before they become signal, and by the time they're being discussed in conference sessions, someone else has already moved. This section maps the structural shifts underway in your therapy area each quarter: volume changes, pricing pressure, new entrants, channel evolution, and buyer behaviour. Not a history lesson. A snapshot of where the ground is moving.
CE marks. FDA clearances. Clinical data releases. Platform pivots. The events that shift competitive conversations before most people have read the press release. This section tracks what your competitors and adjacent players announced during the quarter, with context on what it actually means for the commercial picture, not just what the PR said it meant.
Where the contracts went. Framework awards, tender outcomes, named NHS trust or health system decisions, and procurement windows opening in the next quarter. If you're building a pipeline or managing a distribution strategy, this is where you find out who bought what from whom, and where the next opportunity is most likely to land before your competitors have booked the meeting.
Funding rounds, acquisitions, strategic partnerships, and investor activity across your therapy area. M&A in medical devices rarely stays contained to the companies directly involved: distribution agreements change, sales teams are absorbed, clinical pipelines accelerate or stall, and competitors gain capabilities overnight. This section tracks what's moving financially so you can read the commercial implications before the press release becomes common knowledge.
MHRA guidance. MDR transitions. Post-market surveillance shifts. The regulatory environment in medical devices moves faster than most commercial leaders track, and the consequences of missing a change land on the sales and market access teams first. This section distils the quarter's regulatory activity into what it means commercially: which products are affected, which approval pathways are shifting, and what you need to brief your team on before it becomes a problem in the field.
What the KOLs, clinical leads, and commercial executives who shape your market are actually saying, not in prepared remarks, but in published interviews, conference panels, and industry forums. This section surfaces the opinions and debates that are moving buyer thinking before they harden into policy. If a procurement lead at a major trust is signalling scepticism about a particular clinical claim, you want to know that before your field team walks into the room.
NHS reimbursement decisions, NICE guidance updates, ICS commissioning changes, and CPT or DRG movement in international markets. Reimbursement is where clinical promise meets commercial reality, and changes in payer behaviour consistently arrive before they're reflected in procurement activity. This section is written for commercial leaders who need to keep market access arguments current, and who can't afford to be briefed on reimbursement developments by their distributor after the fact.
Clinical opinion shapes buying decisions before procurement teams formalise them. This section tracks the KOLs, committee members, and advisory board participants who influence your therapy area each quarter: what they're publishing, where they're presenting, and how their stated positions are shifting. If a clinical lead's view on your category is moving, you want to know before it reaches the tender specification.
Commercial leadership changes are one of the highest-value intelligence signals in medical devices. A new VP Sales at a competitor. A market access director who just moved from a payer to a manufacturer. A CEO hire that signals a shift in commercial strategy. This section tracks the appointments, departures, and structural changes across your competitive picture each quarter, because the people moving are almost always the leading indicator of where the strategy is going.
How your competitors are positioning themselves externally. This section covers campaign launches, branded content, speaker activity, conference presence, and messaging shifts across your therapy area. Promotional moves are often the first visible signal of a commercial repositioning: spotted early, they give you time to respond before the message has reached your customers.
This is where the intelligence becomes instruction. Each quarter, this section translates the patterns from the preceding sections into three to five specific commercial actions: conversations to have, tenders to prepare for, competitor vulnerabilities to test, market access arguments to build. These are not generic recommendations. They're written to the specific conditions of your therapy area in that quarter, for leaders who are ready to move on what they know.
Revenue results, guidance revisions, cost restructuring announcements, and investor communications from publicly listed competitors and their parent companies. Financial signals often arrive before their commercial consequences become visible in the field. A competitor reducing sales headcount in your geography, or a parent company flagging margin pressure, usually precedes a change in commercial behaviour within one to two quarters.
This report serves as a strategic compass, transforming a complex landscape into a clear, prioritised execution plan. It moves the commercial function from a reactive footing to a proactive one: identifying where you can influence specifications before they become live tenders.
Some subscribers use this to get up to speed fast. Others use it to make sure they haven't missed anything, or to hold a position that didn't come from anyone who reports to them. Either way, the report tells you what is happening, what it means for your position, and what you should do about it.
Sample Reports
Three full Standard Grade reports. Same format, same source discipline, same fourteen sections as a subscribed report. The Action Intelligence in these reports is written for the therapy area generally. In a subscribed report, it's written around your specific commercial position: informed by your intake brief, your territory, and the competitive questions you've told us matter most.
CPT 75577 permanent reimbursement activation, Medtronic/CathWorks acquisition, NHS Digital Diagnostic Solutions framework, HeartFlow vs Cleerly competitive positioning, and three RED-rated 90-day priorities.
Read sample reportIntuitive Surgical procedure volume data, NICE technology appraisal pipeline, NHS robotic surgery hub network expansion, competitive positioning across CMR, Medicaroid, and J&J platforms, and three RED-rated 90-day priorities.
Read sample reportGIRFT elective recovery targets, NHS joint replacement framework activity, US ASC migration signals, and competitive landscape across primary and revision surgery markets.
Read sample reportThree ways in
Three formats. Each built for a different commercial situation. All written for one buyer, not a market category.
Sample
One full report. Your therapy area and geography. Read the product before you commit to it.
Market Brief
A complete commercial picture of your therapy area and geography. 20 to 25 pages. Every section. Written for one buyer, not a market category.
Billed per report via Stripe. Invoice provided automatically on payment. By purchasing you accept the BI Subscription Terms.
Reference Grade
Board-level intelligence. Everything in the Market Brief plus named buyer contacts, KOL mapping, and a bespoke strategic frame written for your specific commercial situation.
Billed per report via Stripe. Invoice provided automatically on payment. By purchasing you accept the BI Subscription Terms.
Four times a year, filtered to your market. Delivered before the quarter opens.
Questions before subscribing? Read the FAQ below
The Innotech Business Intelligence Report is a quarterly commercial intelligence briefing for senior leaders in medical devices. It covers a named therapy area and geography: competitive landscape, regulatory and reimbursement developments, procurement activity, M&A and investment signals, talent moves, and earnings data. It closes with Action Intelligence: three specific priorities for the next 90 days, each grounded in what the research found.
Every claim is sourced. Every figure is named. There are no estimates presented as facts and no generic market commentary. The report is built specifically for commercial leaders who need to act on intelligence, not just read it.
Every retained search Innotech runs starts with a detailed read of the market: who is hiring, who has just been funded, which companies are pivoting their commercial strategy, and which are quietly building ahead of a product launch. That intelligence is gathered systematically, therapy area by therapy area, as a direct byproduct of operating at director and board level across the UK, US, and Republic of Ireland.
The BI Report makes that intelligence available to the people who can act on it, not just the companies who hired Innotech to find someone.
Founders, CEOs, Managing Directors, VP Sales, VP Marketing, Market Access Directors, and Commercial Directors operating in medical devices across the UK, US, and Republic of Ireland. The report is written for someone who already knows the market and needs to know what is moving in it right now. It is not a primer on the therapy area.
If you are unsure whether it fits your situation, the sample reports above are full Standard Grade issues. Read one and see if the format is what you need.
Current Standard Grade reports are available in cardiovascular imaging AI, surgical robotics, and orthopaedics. Geographies covered are United States, United Kingdom, and Republic of Ireland, individually or in combination.
If your therapy area or geography is not listed, a Reference Grade bespoke commission can be produced for any medical device commercial leadership market. Contact Blair Anderson to discuss scope.
Fifteen sections: market snapshot, major announcements and product advancements, business wins and procurement activity, M&A and investment activity, UK funding and investment tracker, competitive landscape, horizon intelligence, regulatory and compliance updates, reimbursement and payer intelligence, expert opinions and KOL intelligence, digital and social listening, global events calendar, talent and commercial intelligence, earnings and financial signals, and Action Intelligence.
Every report also includes a “What Is Not In This Report and Why” section: a transparent statement of what the research could not verify and what the Reference Grade provides instead.
Action Intelligence is the final section of every report. It translates everything the research found into three specific commercial priorities for the next 90 days, each classified RED (act now), AMBER (monitor closely), or GREEN (track, no immediate action required).
Each priority states the action, the intelligence basis for it citing specific findings from the report, and the consequence of not acting. In a subscribed report, these priorities are written around your company’s specific commercial position, not the category in general.
Three things distinguish it. Every claim is sourced: named organisation, named document, named date. No unattributed statistics, no estimated figures presented as fact. It is written for a specific commercial audience making specific decisions. And it closes with Action Intelligence: a specific 90-day agenda, not a summary of what was covered.
Generic market research describes the market. This report tells you what to do about it on Monday.
Yes. Sample reports are available above for cardiovascular imaging AI, surgical robotics, and orthopaedics. These are full Standard Grade reports. The only difference from a subscribed report is that the Action Intelligence section is written for the category generally, not for your specific commercial position.
There are three ways to access Innotech BI. The Sample is free: one full report, your therapy area and geography, delivered within five working days. The Market Brief is priced at £2,950 / $3,700 / €3,450 per report, depending on geography. The Reference Grade (which adds named buyer contacts, KOL mapping, and bespoke strategic framing) is priced at £4,500 / $5,650 / €5,250 per report. All reports are priced per commission. There is no subscription lock-in and no annual commitment required. Payment is handled via Stripe and an invoice is issued automatically on payment.
Not in the traditional sense. There is no annual subscription or quarterly lock-in. You commission a report when you need one and pay per report. Repeat buyers receive priority turnaround and Blair Anderson will flag relevant intelligence between commissions if something significant moves in your market. The product is designed to earn repeat business on quality, not retain it on contract.
Yes. Bank transfer is available where card payment is not practical for procurement reasons. Email blair.anderson@innotechrecruit.com and a proforma invoice with bank details will be provided.
Reports are delivered in the first week of each quarter: by the end of the first Friday of January, April, July, and October. Your delivery date is confirmed in your order confirmation. If a report is delayed beyond the first week, Blair Anderson will contact you before the due date.
By email as a PDF attachment, sent directly from blair.anderson@innotechrecruit.com to the address registered on your subscription. The report is named to you and marked confidential on the cover page. It is not shared with any other subscriber. Check your spam folder if it has not arrived: some corporate email systems filter PDF attachments from outside your domain.
Market Brief reports are single-user licences: the report is for your use only. Short extracts may be cited in internal presentations with clear attribution to Innotech Recruit. Sharing the full report externally or with third parties outside your organisation is not permitted under a Market Brief licence.
To extend access to your wider team, email Blair Anderson to discuss a site or corporate licence.
Market Brief is built entirely from publicly available, named, and verifiable sources. Reference Grade goes further. It includes named buyer contacts at health-system or NHS trust level, KOL mapping with verified committee memberships and commercial affiliations, employee sentiment intelligence from named platforms, and a bespoke commissioning brief built around your specific commercial situation.
Reference Grade reports are commissioned for a specific company and a specific commercial situation. They are not a subscription product: each is a standalone commission.
Email Blair Anderson at blair.anderson@innotechrecruit.com or call +44 779 367 1203. The conversation starts with your commercial situation: what decision you are trying to make and what intelligence would change or confirm it. Scope and pricing are agreed before any research begins. Reference Grade commissions are priced from £4,500 / $5,650 / €5,250.
Each report is produced using Innotech SIGNAL Intelligence: a structured research methodology drawing on regulatory databases, company filings, NHS procurement frameworks, payer policy documents, peer-reviewed publications, earnings transcripts, and named trade press. Research is conducted across a 90-day window and synthesised into the report structure. All sources are listed by name and date at the end of every report.
AI research tools are used in the production pipeline: Perplexity AI for primary research, Grok for the secondary pass on regulatory and personnel sections, and Claude AI for synthesis and structuring. Each tool operates under a strict source discipline protocol: claims without a named, verifiable primary or secondary source are excluded, not estimated.
The fabrication audit and final editorial review are conducted by Blair Anderson before every report ships. No AI-generated content that has not been verified against a named source appears in a published report.
Your name, job title, company, work email address, geography and therapy area preferences, questionnaire responses, and payment confirmation records. Full detail, including retention periods and third-party processors, is in the BI Subscriber Privacy Notice at privacy.innotechrecruit.com/bi.
Your data is never sold. It is not shared with competitors in your therapy area. It is processed by a small number of named third-party platforms: Stripe (payment), HubSpot (subscription management), and the AI research tools used in production, all under data processing agreements.
Email blair.anderson@innotechrecruit.com at least 30 days before your next renewal date. No reason is required. Blair will confirm cancellation in writing and ensure no further charges are made. Full cancellation terms are in the BI Subscription Terms at terms.innotechrecruit.com/bi.